Sherwood, Oregon--(PRNewswire - December 17, 2012) – Entia Biosciences (OTCBB: ERGO), a food science biotechnology company and emerging leader in the fields of Nutrigenomics and Targeted Nutrition, has received a Patent Notice of Allowance from the Canadian Intellectual Property Office covering the use of Ergothioneine and its genetic transporter (SLC22A4) in the treatment of a wide variety of diseases, including those affecting the immune and central nervous systems. Ergothioneine is a powerful amino acid and master antioxidant that is acquired exclusively from the diet and carried by this unique and specific transporter to cells throughout the body that are fighting damage and death from oxidative stress and toxic free radical reactions. Research conducted by Entia since 2011 has confirmed significant transporter activity in diabetes, arthritis, and several other serious non-communicable chronic conditions, suggesting an important physiologic roll for Ergothioneine in diseases affecting millions of people world-wide.
"We are very
pleased that our intellectual property estate on Ergothioneine is advancing
nicely alongside the scientific, clinical and other business developments at
Entia," said Marvin S. Hausman MD, Chairman and Chief Executive Officer.
"The issuance of this important foundational patent significantly
enhances the commercialization strategy for our
ErgoD2™ line of proprietary medical foods, functional
ingredients, and other nutritional supplementation solutions in 2013 and for
the potential development of a commercial diagnostic test that could one day
identify specific dietary deficiencies.”
Found in naturally high
concentrations almost exclusively in mushrooms and other fungi, Ergothioneine
is transferred directly from these sources into the soil, where it is taken up
by plants and grazing mammals. For thousands
of years, our hunter/gatherer genetics have relied on this process to maintain
adequate levels of Ergothioneine to prevent or delay the onset and progression
of disease. Entia theorizes
introduction of modern agricultural practices in the past century, such as the
heavy use of chemical fertilizers, insecticides, and over tilling of the soil,
has been gradually eradicating mushrooms from our farmland and depleting
Ergothioneine from the food supply. During
this same period, our dietary habits have been changing, which Entia believes is further accelerating
deficiency in the general population and may explain the dramatic increases we
are now seeing in diabetes, arthritis, neurodegenerative, and other
debilitating diseases. This deficiency
theory is supported by human blood testing conducted in the late 1920s
that showed “normal” Ergo levels nearly double those found by Pennsylvania
State University in 2010.
Discovered in 2005 by Dr. Dirk Gründemann at the
University of Cologne (Germany), SLC22A4 is a sodium-ion dependent transporter that efficiently and specifically carries Ergothioneine
across the cell membrane to erythrocytes (red blood cells), progenitor stem
cells, and monocytes (white blood cells) (Gründemann, 2005). Variations in
SLC22A4 have been associated with susceptibility to inflammatory disorders,
such as rheumatoid arthritis and Crohn's disease, and expression has been
documented in a variety of human tissues. Entia licensed the exclusive world-wide
diagnostic and therapeutic rights to the discovery from the University of
Cologne in 2010 and Dr. Gründemann currently serves on Entia’s Scientific
Dr. Solomon Snyder of Johns Hopkins
University School of Medicine has suggested that Ergothioneine is as potent as
glutathione and because of its dietary origin and the toxicity associated with
its depletion, it may represent a new vitamin whose physiologic roles include
antioxidant cytoprotection. Dr. Snyder
further believes that the high density of Ergothioneine within mitochondria
implies a unique role in protecting mitochondrial DNA from damage induced by
free radicals and reactive oxygen species (Snyder, 2009). Mitochondria are
cytoplasmic organelles responsible for life and death. Evidence from animal and clinical studies
suggest that mitochondria play a critical role in aging, cancer, diabetes and
neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease
(Simon, 2004; Lin, 2006; Reddy, P.H., 2009).
Further supportive evidence of the potential protective role of Ergothioneine was recently shown by the presence of elevated levels in the red blood cells of pregnant women with the condition preeclampsia. There is currently no known cause for this condition, which affects nearly 10% of pregnancies reaching 20 weeks. The symptoms of preeclampsia include high blood pressure, protein in urine, and fluid retention and left untreated the condition can cause a range of problems such as growth restriction in babies and even fetal and maternal mortality. Ergothioneine is known as an antioxidant and antioxidants have been proposed to be helpful in reducing the risk of preeclampsia. It is therefore very interesting that we have found it to be in excess for women with the condition (Turner, E., 2009).”
About Entia Biosciences, Inc.
Entia is an authority on the clinical
effects of oxidative stress and free radical reactions and is bringing this expertise
to the fields of food science biotechnology and nutrigenomics. The Company identifies, scientifically
validates, patents, and commercializes solutions that address multi-billion
dollar markets for health, beauty and agriculture.
For more information, please visit our web sites at www.entiabio.com or contact:
Entia Biosciences, Inc.
13565 SW Tualatin-Sherwood Rd Sherwood, OR, 97140
Phone: 503-334-3575 Email: firstname.lastname@example.org
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2011 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
 Harold Bernard Salt, “The Ergothioneine Content of the Blood in Health and Disease,” August 27, 1931.
 Weigand-Heller et al, “The bioavailability of ergothioneine from mushrooms (Agaricus bisporus) and the acute effects on antioxidant capacity and biomarkers of inflammation.” Preventive Medicine (2012),54:575-578.